The Intensified Treatment Monitoring Strategy to Prevent Accumulation of Drug Resistance (ITREMA) Trial

NACompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

June 29, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

May 31, 2022

Conditions
HIV/AIDS
Interventions
OTHER

Intensified monitoring

Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.

OTHER

Standard of care monitoring

Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.

Trial Locations (1)

0485

Ndlovu Medical Centre, Elandsdoorn

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Ndlovu Care Group

UNKNOWN

collaborator

Wits Reproductive Health and HIV Institute

OTHER

lead

UMC Utrecht

OTHER

NCT03357588 - The Intensified Treatment Monitoring Strategy to Prevent Accumulation of Drug Resistance (ITREMA) Trial | Biotech Hunter | Biotech Hunter